Analyst Sees Strong Zusduri Upside, Lifts UroGen Pharma Price Target from $35 to $50 with Buy Rating
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Tara Bancroft raised UroGen Pharma's price target from $35 to $50, maintaining a Buy rating. The upgrade reflects strong demand for Zusduri, with Q2 revenue expected to beat estimates and 2026 sales projected above consensus. Guggenheim also issued a Buy rating with a $42 target. URGN stock has surged 112.73% over six months.
TD Cowen analyst Tara Bancroft maintained a Buy rating on Urogen Pharma yesterday and set a price target of $50.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Tara Bancroft has given his Buy rating due to a combination of factors tied to UroGen Pharma’s core product, Zusduri, and its anticipated performance. He expects second-quarter Zusduri revenue to surpass market expectations, reflecting robust underlying demand and positive feedback from leading physicians, which supports a more optimistic outlook on the company’s near-term growth.
Looking further ahead, Bancroft projects 2026 Zusduri sales meaningfully above current Street estimates, arguing that prevailing consensus remains cautious relative to the product’s trajectory. Incorporating these higher assumptions into a discounted cash flow framework leads him to raise his price target from $35 to $50, reinforcing the view that URGN shares offer attractive upside and justifying his Buy recommendation.
In another report released today, Guggenheim also assigned a Buy rating to the stock with a $42.00 price target.
URGN’s price has also changed dramatically for the past six months – from $19.330 to $41.120, which is a 112.73% increase.